NCT03619993 (CONVENIENCE) is a NA clinical trial of On-body injector in Non Hodgkin Lymphoma, sponsored by iOMEDICO AG.

Who is sponsoring NCT03619993?

NCT03619993 is sponsored by iOMEDICO AG.

What drugs are being tested in NCT03619993?

Interventions in NCT03619993: On-body injector, Pre-filled syringe.

What condition does NCT03619993 study?

NCT03619993 studies Non Hodgkin Lymphoma, Breast Cancer.

Is NCT03619993 still recruiting?

NCT03619993 is currently completed. Last updated 17 December 2019.

Last reviewed 2019-12-17 · How we verify

NCT03619993: CONVENIENCE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Patient Preference for Pegfilgrastim (Neulasta®) Application Forms

Completed NA Last updated 17 December 2019

What this trial tests

NA trial testing On-body injector in Non Hodgkin Lymphoma in 404 participants. Completed in 10 September 2019.

Timeline

25 June 2018

Primary endpoint
10 September 2019

10 September 2019

Quick facts

Lead sponsor	iOMEDICO AG
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	404
Start date	25 June 2018
Primary completion	10 September 2019
Estimated completion	10 September 2019
Sites	48 locations across Germany

Drugs / interventions tested

On-body injector
Pre-filled syringe

Conditions studied

Non Hodgkin Lymphoma — all drugs for Non Hodgkin Lymphoma →
Breast Cancer — all drugs for Breast Cancer →

Sponsor

iOMEDICO AG — full company profile →

Who can join

18 and older, any sex, with Non Hodgkin Lymphoma or Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims to compare two application forms (pre-filled syringe and On-body injector) of the same active drug (pegfilgrastim) in adult patients under chemotherapy regarding patient preference and health economics. Chemotherapy will be supported with pegfilgrastim for four subsequent chemotherapy cycles using alternating application forms.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Patient, nurse, and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector in cancer patients.
Metz M, Semsek D, Rogmans G, Hutzschenreuter U, et al · · 2021 · cited 10× · PMID 33956213 · DOI 10.1007/s00520-021-06230-9

Verify or expand the search:

Other recruiting trials for Non Hodgkin Lymphoma

Currently open trials in the same condition.

NCT07410494 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07016165 — Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Maligna · Phase 4 · recruiting
NCT06622226 — A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma · Phase 1 · active not recruiting
NCT06522932 — PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy · Phase 1 · recruiting
NCT06116110 — Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU · recruiting

Other iOMEDICO AG trials

Trials by the same sponsor.

NCT06619275 — Ripretinib (QINLOCK®) According to Current SmPC · completed
NCT06181734 — Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC · completed
NCT05954780 — Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma · active not recruiting
NCT05517265 — Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO) · active not recruiting
NCT05284591 — Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03619993 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by iOMEDICO AG
Last refreshed: 17 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03619993.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing